AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1984328 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat suppression
Number of subjects: 28
Study 1984328 — intervention group
Group type: COMPARATOR
Intervention: TE of 20 msec
Number of subjects: 28
Study 1984328 — intervention group
Group type: COMPARATOR
Intervention: No fat suppression
Number of subjects: 28
Study 3915287 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime prophylaxis (1.5g every 12 h for 2 days)
Number of subjects: 512
Study 3915287 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone prophylaxis (2g i.v. plus 1g i.v. after 24 h for 2 days)
Number of subjects: 512
Study 3915287 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone prophylaxis
Number of subjects: 512
Study 3915287 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime and Ceftriaxone prophylaxis
Number of subjects: 512
Study 29469602 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive prone press-ups
Number of subjects: 41
Study 29469602 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained prone press-ups
Number of subjects: 41
Study 29469602 — intervention group
Group type: COMPARATOR
Intervention: Time (before vs. after press-ups)
Number of subjects: 41
Study 29469602 — intervention group
Group type: COMPARATOR
Intervention: End range of motion spinal extension
Number of subjects: 41
Study 29498469 — intervention group
Group type: EXPERIMENTAL
Intervention: vildagliptin (50 mg twice daily)
Number of subjects: 28
Study 29498469 — intervention group
Group type: COMPARATOR
Intervention: dapagliflozin (10 mg once daily)
Number of subjects: 28
Study 26888258 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (10 mg/m² per day for 3 weeks plus tapering)
Number of subjects: 3720
Study 26888258 — intervention group
Group type: COMPARATOR
Intervention: Prednisone (60 mg/m² per day for 3 weeks plus tapering)
Number of subjects: 3720
Study 26888258 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 3720
Study 26888258 — intervention group
Group type: COMPARATOR
Intervention: Prednisone
Number of subjects: 3720
Study 24020994 — intervention group
Group type: EXPERIMENTAL
Intervention: SumaRT/Nap (85 mg sumatriptan + 500 mg naproxen sodium)
Number of subjects: 28
Study 24020994 — intervention group
Group type: COMPARATOR
Intervention: naproxen sodium (500 mg)
Number of subjects: 28
Study 22503574 — intervention group
Group type: EXPERIMENTAL
Intervention: 18 mg nicotine e‐cigarette
Number of subjects: 86
Study 22503574 — intervention group
Group type: COMPARATOR
Intervention: 0 mg e‐cigarette (placebo)
Number of subjects: 86
Study 22503574 — intervention group
Group type: COMPARATOR
Intervention: just hold e‐cigarette
Number of subjects: 86
Study 20374673 — intervention group
Group type: EXPERIMENTAL
Intervention: Learning potential (LP) indices from a test‐train‐test version of a list‐learning task
Number of subjects: 43
Study 20374673 — intervention group
Group type: EXPERIMENTAL
Intervention: Test‐retest reliability and interrelatedness of LP indices
Number of subjects: 43
Study 22360905 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan-coated suture group (170 patients)
Number of subjects: 510
Study 22360905 — intervention group
Group type: COMPARATOR
Intervention: Noncoated suture group (340 patients)
Number of subjects: 510
Study 15988695 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (12.5 mg/h IV)
Number of subjects: 6
Study 15988695 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 6
Study 12663105 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar electrodissection tonsillectomy (BET)
Number of subjects: 60
Study 12663105 — intervention group
Group type: COMPARATOR
Intervention: Cold dissection tonsillectomy (CDT)
Number of subjects: 60
Study 9608969 — intervention group
Group type: EXPERIMENTAL
Intervention: Scheduled administration of acetaminophen (60 mg.kg-1.24h-1 orally, 90 mg.kg-1.24h-1 rectally)
Number of subjects: 40
Study 9608969 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen 'as needed' (control group)
Number of subjects: 40
Study 7658599 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg recombinant human GH for 7 to 13 days
Number of subjects: 16
Study 7658599 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 2787561 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 40
Study 2787561 — intervention group
Group type: COMPARATOR
Intervention: Thiopental
Number of subjects: 40
Study 2787561 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 40
Study 791331 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol
Number of subjects: 18
Study 791331 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 18
Study 31077729 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-to-severe insight impairment
Number of subjects: 3
Study 31077729 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal insight impairment
Number of subjects: 3
Study 31077729 — intervention group
Group type: EXPERIMENTAL
Intervention: No insight impairment
Number of subjects: 3
Study 31138244 — intervention group
Group type: EXPERIMENTAL
Intervention: VRD + elotuzumab (B1 + B2)
Number of subjects: 564
Study 31138244 — intervention group
Group type: COMPARATOR
Intervention: VRD (A1 + A2)
Number of subjects: 564
Study 28475943 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing Treatment Integrity coding system 4.2 (MITI 4.2)
Number of subjects: 22
Study 25176939 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose (FCM, n = 152)
Number of subjects: 304
Study 25176939 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline, n = 152)
Number of subjects: 304
Study 23260747 — intervention group
Group type: EXPERIMENTAL
Intervention: Canola protein isolate (CPI)
Number of subjects: 28
Study 23260747 — intervention group
Group type: EXPERIMENTAL
Intervention: Canola protein hydrolyzate (CPH)
Number of subjects: 28
Study 23260747 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein isolate (SPI)
Number of subjects: 28
Study 23260747 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrogen balance
Number of subjects: 28
Study 21982529 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole 200 mg three times per week
Number of subjects: 1519
Study 21982529 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1519
Study 21982529 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole
Number of subjects: 1519
Study 18496341 — intervention group
Group type: EXPERIMENTAL
Intervention: Bryan Disc arthroplasty
Number of subjects: 463
Study 18496341 — intervention group
Group type: COMPARATOR
Intervention: Anterior cervical discectomy and fusion
Number of subjects: 463
Study 16522388 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic group (oral azithromycin 1 g twice, plus metronidazole 750 mg daily for 7 days)
Number of subjects: 241
Study 16522388 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (identical-appearing placebos)
Number of subjects: 241
Study 14661817 — intervention group
Group type: EXPERIMENTAL
Intervention: Training groups
Number of subjects: 203
Study 14661817 — intervention group
Group type: COMPARATOR
Intervention: Control groups
Number of subjects: 203
Study 10639034 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mmol Gd/kg (group 1)
Number of subjects: 21
Study 10639034 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mmol Gd/kg (group 1)
Number of subjects: 21
Study 10639034 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mmol Gd/kg (group 2)
Number of subjects: 21
Study 10639034 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mmol Gd/kg (group 2)
Number of subjects: 21
Study 8699051 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg of sorivudine
Number of subjects: 186
Study 8699051 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 186
Study 1526858 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily treatment regimen delivering 2 Gy per fraction
Number of subjects: 203
Study 1526858 — intervention group
Group type: COMPARATOR
Intervention: Once weekly treatment regimen delivering 5.4 Gy per fraction
Number of subjects: 203
Study 3884122 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide-amiloride hydrochloride (Moduret)
Number of subjects: 266
Study 3884122 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide alone
Number of subjects: 266
Study 29794092 — intervention group
Group type: EXPERIMENTAL
Intervention: Gelatine tannate (250-500 mg, four times per day for 5 days)
Number of subjects: 72
Study 29794092 — intervention group
Group type: COMPARATOR
Intervention: Placebo (four times per day for 5 days)
Number of subjects: 72
Study 29794092 — intervention group
Group type: EXPERIMENTAL
Intervention: Gelatine tannate
Number of subjects: 72
Study 29794092 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 25489672 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic lavage
Number of subjects: 83
Study 25489672 — intervention group
Group type: COMPARATOR
Intervention: Hartmann procedure (Control)
Number of subjects: 83
Study 24813026 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine (60‐120 mg once daily, n=117)
Number of subjects: 337
Study 24813026 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (20‐40 mg once daily, n=117)
Number of subjects: 337
Study 24813026 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=103)
Number of subjects: 337
Study 24813026 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 337
Study 24813026 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 337
Study 24813026 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 337
Study 22016361 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive home visit program (structured visits every 6 months for 2 years)
Number of subjects: 323
Study 22016361 — intervention group
Group type: COMPARATOR
Intervention: Control group (no preventive home visits)
Number of subjects: 323
Study 20033907 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 139
Study 20033907 — intervention group
Group type: EXPERIMENTAL
Intervention: Atypical antipsychotics (risperidone, olanzapine, aripiprazole)
Number of subjects: 139
Study 20033907 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 139
Study 18753666 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramlintide 120 microg t.i.d.
Number of subjects: 411
Study 18753666 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramlintide 360 microg b.i.d.
Number of subjects: 411
Study 18753666 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 411
Study 15354199 — intervention group
Group type: EXPERIMENTAL
Intervention: Very-low-protein diet supplemented with ketoacids (VLPD+KA)
Number of subjects: 24
Study 15354199 — intervention group
Group type: COMPARATOR
Intervention: Conventional low-protein diet (LPD)
Number of subjects: 24
Study 12116051 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyzide (Julphar, UAE)
Number of subjects: 24
Study 12116051 — intervention group
Group type: COMPARATOR
Intervention: Diamicron (Servier Industries, France)
Number of subjects: 24
Study 10566499 — intervention group
Group type: EXPERIMENTAL
Intervention: Newton MessagePad outfitted with custom software (AsthMonitor) for documentation and guideline recommendations
Number of subjects: 9
Study 10566499 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommendations provided by AsthMonitor
Number of subjects: 9
Study 8567844 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined leuprolide (3.75 mg every 27 days) plus conventional therapy (group A)
Number of subjects: 24
Study 8567844 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy alone (group B)
Number of subjects: 24
Study 8567844 — intervention group
Group type: COMPARATOR
Intervention: GnRHa treatment (group C)
Number of subjects: 24
Study 2358736 — intervention group
Group type: EXPERIMENTAL
Intervention: Infrared photocoagulation (IRC)
Number of subjects: 200
Study 2358736 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (CT) by injection sclerotherapy or rubber band ligation
Number of subjects: 200
Study 2358736 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (CT)
Number of subjects: 200
Study 2358736 — intervention group
Group type: EXPERIMENTAL
Intervention: Rubber band ligation (RBL)
Number of subjects: 200
Study 526396 — intervention group
Group type: EXPERIMENTAL
Intervention: labetalol Css
Number of subjects: 17
Study 30733143 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tsDCS + BLT
Number of subjects: 43
Study 30733143 — intervention group
Group type: COMPARATOR
Intervention: Sham tsDCS + BLT
Number of subjects: 43
Study 30733143 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Anodal tsDCS + BLT and Sham tsDCS + BLT)
Number of subjects: 43
Study 27468907 — intervention group
Group type: EXPERIMENTAL
Intervention: Pose SM intervention (gastric fundus and distal body suture-anchor plications with diet/exercise counseling)
Number of subjects: 44
Study 27468907 — intervention group
Group type: EXPERIMENTAL
Intervention: Pose SM intervention
Number of subjects: 44
Study 27468907 — intervention group
Group type: COMPARATOR
Intervention: Control (diet/exercise guidance only)
Number of subjects: 44
Study 26383695 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive Behavioural Modification Therapy (IBMT)
Number of subjects: 57
Study 26383695 — intervention group
Group type: COMPARATOR
Intervention: Progressive Neck Exercise Programme (PNEP)
Number of subjects: 57
Study 24126796 — intervention group
Group type: EXPERIMENTAL
Intervention: Log-transformed PORPUS-U without hierarchy constraint
Number of subjects: 676
Study 24126796 — intervention group
Group type: EXPERIMENTAL
Intervention: Original PORPUS-U scores
Number of subjects: 676
Study 24126796 — intervention group
Group type: EXPERIMENTAL
Intervention: Log-transformed PORPUS-U with hierarchy constraint
Number of subjects: 676
Study 24126796 — intervention group
Group type: EXPERIMENTAL
Intervention: Mapping algorithm for calculating PORPUS-U from PCI scores
Number of subjects: 676
Study 21788373 — intervention group
Group type: EXPERIMENTAL
Intervention: FTO rs17817449 genotype GG
Number of subjects: 1188
Study 21788373 — intervention group
Group type: EXPERIMENTAL
Intervention: FTO rs17817449 genotype GT
Number of subjects: 1188
Study 21788373 — intervention group
Group type: COMPARATOR
Intervention: Control group (TT genotype)
Number of subjects: 1188
Study 19284932 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 70
Study 19284932 — intervention group
Group type: COMPARATOR
Intervention: Sertraline
Number of subjects: 70
Study 19284932 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (Nortriptyline and Sertraline)
Number of subjects: 70
Study 17542209 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% sodium fluoride bioerodible resin
Number of subjects: 36
Study 17542209 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% sodium fluoride varnish
Number of subjects: 36
Study 17542209 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 36
Study 15855970 — intervention group
Group type: EXPERIMENTAL
Intervention: Light-induced fluorescence endoscopy (LIFE)
Number of subjects: 50
Study 15855970 — intervention group
Group type: COMPARATOR
Intervention: Standard endoscopy (SE)
Number of subjects: 50
Study 11932564 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training program for 12 weeks at 65-70% of work capacity
Number of subjects: 25
Study 11932564 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 25
Study 9150811 — intervention group
Group type: EXPERIMENTAL
Intervention: Selegiline
Number of subjects: 44
Study 9150811 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 8197035 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac tromethamine 10 mg
Number of subjects: 160
Study 8197035 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen 400 mg plus paracetamol 325 mg
Number of subjects: 160
Study 8197035 — intervention group
Group type: COMPARATOR
Intervention: Dextropropoxyphene 65 mg plus paracetamol 400 mg
Number of subjects: 160
Study 3592300 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (0.01, 0.02, 0.03, and 0.04 mg/kg IV)
Number of subjects: 20
Study 3592300 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol (0.001, 0.002, 0.003, and 0.004 mg/kg IV)
Number of subjects: 20
Study 31358477 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone (200 mg testosterone enanthate per week)
Number of subjects: 50
Study 31358477 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 29978417 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention (MBI)
Number of subjects: 82
Study 29978417 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 82
Study 27767947 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational therapy intervention
Number of subjects: 11
Study 27767947 — intervention group
Group type: COMPARATOR
Intervention: Standard care intervention
Number of subjects: 11
Study 25223181 — intervention group
Group type: EXPERIMENTAL
Intervention: Qingfei Peiyuan Micro‐pill (QPM)
Number of subjects: 141
Study 25223181 — intervention group
Group type: COMPARATOR
Intervention: Control group (Western medicine only)
Number of subjects: 141
Study 23610857 — intervention group
Group type: EXPERIMENTAL
Intervention: Wrist angulation at 30 degrees (Group 30)
Number of subjects: 60
Study 23610857 — intervention group
Group type: EXPERIMENTAL
Intervention: Wrist angulation at 45 degrees (Group 45)
Number of subjects: 60
Study 23610857 — intervention group
Group type: EXPERIMENTAL
Intervention: Wrist angulation at 60 degrees (Group 60)
Number of subjects: 60
Study 19340466 — intervention group
Group type: EXPERIMENTAL
Intervention: Leaflet instruction group
Number of subjects: 99
Study 19340466 — intervention group
Group type: EXPERIMENTAL
Intervention: Demonstration group
Number of subjects: 99
Study 19340466 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 99
Study 18831737 — intervention group
Group type: EXPERIMENTAL
Intervention: Microscopy-based diagnosis (Arm-I)
Number of subjects: 3171
Study 18831737 — intervention group
Group type: COMPARATOR
Intervention: Clinical algorithm only (Arm-II)
Number of subjects: 3171
Study 18831737 — intervention group
Group type: COMPARATOR
Intervention: No training (Arm-III)
Number of subjects: 3171
Study 15877221 — intervention group
Group type: EXPERIMENTAL
Intervention: Open kinetic chain (OKC) knee extensor resistance training
Number of subjects: 64
Study 15877221 — intervention group
Group type: COMPARATOR
Intervention: Closed kinetic chain (CKC) knee extensor resistance training
Number of subjects: 64
Study 15322960 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily extended-release methylphenidate
Number of subjects: 79
Study 15322960 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily immediate-release methylphenidate
Number of subjects: 79
Study 15322960 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study 10636265 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin
Number of subjects: 364
Study 10636265 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 364
Study 9301060 — intervention group
Group type: EXPERIMENTAL
Intervention: Superdirective processing
Number of subjects: 0
Study 9301060 — intervention group
Group type: EXPERIMENTAL
Intervention: Delay-and-sum beamforming
Number of subjects: 0
Study 9301060 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardioid microphone
Number of subjects: 0
Study 9301060 — intervention group
Group type: EXPERIMENTAL
Intervention: Single omnidirectional microphone
Number of subjects: 0
Study 9301060 — intervention group
Group type: COMPARATOR
Intervention: Single directional microphone (cardioid response pattern)
Number of subjects: 0
Study 7693770 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 9
Study 7693770 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 9
Study 2994320 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy
Number of subjects: 0
Study 2994320 — intervention group
Group type: COMPARATOR
Intervention: Immediate surgery
Number of subjects: 0
Study 2994320 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy
Number of subjects: 0
Study 2994320 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative therapy (chemotherapy or radiotherapy)
Number of subjects: 0
Study 3280589 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone (DMP) administration
Number of subjects: 7
Study 31433919 — intervention group
Group type: EXPERIMENTAL
Intervention: Serelaxin (30 μg per kilogram of body weight per day) for 48 hours
Number of subjects: 6545
Study 31433919 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6545
Study 27786603 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel (18.75 mg/cat q24h for seven days)
Number of subjects: 14
Study 27786603 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 25394856 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycine air‐powder system (SGA) adjuncted to professional oral hygiene (POH)
Number of subjects: 30
Study 25394856 — intervention group
Group type: COMPARATOR
Intervention: Professional oral hygiene (POH)
Number of subjects: 30
Study 25394856 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (SGA and POH)
Number of subjects: 30
Study 22581270 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (n = 111)
Number of subjects: 161
Study 22581270 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy
Number of subjects: 161
Study 21736844 — intervention group
Group type: EXPERIMENTAL
Intervention: Lupin beverage (50 g glucose + 12.5 g fibre + 22 g protein)
Number of subjects: 24
Study 21736844 — intervention group
Group type: EXPERIMENTAL
Intervention: Soya beverage (50 g glucose + 12.5 g fibre + 22 g protein)
Number of subjects: 24
Study 21736844 — intervention group
Group type: EXPERIMENTAL
Intervention: Lupin beverage
Number of subjects: 24
Study 21736844 — intervention group
Group type: EXPERIMENTAL
Intervention: Soya beverage
Number of subjects: 24
Study 20101858 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose misoprostol (maximum total dose 1400 g)
Number of subjects: 60